OBJECTIVES: IDA/IDS is common in pregnancy, postpartum, infl ammatory bowel disease, chronic kidney disease, chronic heart failure, menorrhagia/hypermenorrhagia, cancer and following surgery. We estimate the BI associated with substituting iron sucrose (standard) with ferric carboxymaltose (new treatment), which allows for the application of higher dosages in a shorter time. The analysis adopted the perspective of the Swiss mandatory health insurance (MHI) covering the above indications and is based on real-life data to verify the hypothetical BI estimated prior to launch. METHODS: Resource use (no. of patients, dosage per application, no. of applications) was based on recent primary data (Polyquest Prescriber Analysis, Anemia Patient Record Study in Switzerland). Personnel costs were estimated using the Swiss Tarmed fee-for-service reimbursement system. Drug costs and costs of materials used were based on offi cial tariffs (Spezialitätenliste, MiGeL). Real-life IMS sales data of both products were used to verify the BI model. RESULTS: Ferric carboxymaltose was associated with cost savings of 30-44% compared to iron sucrose based on costs of CHF 101/ 210/ 420 and CHF 144/ 375/ 721 per 200/ 500/ 1000 mg treatment cycle, respectively. This leads to cost savings of CHF 15-33 million per year to the Swiss MHI across all indications in the fi rst 3 years post-launch, due to reductions in personnel costs. Ferric carboxymaltose was shown to be cost-saving in all indications except dialysis (due to fl at-fee reimbursement). Sensitivity analyses showed the amount of cost savings to be sensitive to changes in the number of inpatients (10-20% of total) treated with intravenous iron (due to fl at-fee reimbursement). CONCLUSIONS: Treating IDA/IDS involves substantial costs to the Swiss MHI. Substitution of iron sucrose with ferric carboxymaltose may help to reduce these due to reduced personnel costs. This novel type of real-life BIA will be of increasing interest as conditional reimbursement increases.
PSY13 COST IMPACT FROM INITIATING PREGABALIN TREATMENT IN PATIENTS WITH REFRACTORY NEUROPATHIC PAIN
Myrén KJ 1 , Löfroth E 1 , Sandelin R 2 1 IMS Health, Stockholm, Sweden; 2 Pfi zer, Sollentuna, Sweden OBJECTIVES: To compare the health care costs 6 months prior to and 6 months after initiation of pregabalin in diffi cult-to-treat neuropathic pain (NeP) patients.
METHODS:
This was a retrospective longitudinal database study in NeP patients from the South-West region of Sweden (1.5 million inhabitants). Individual patient data from the 1 st of January 2000 on health care visits (outpatient, inpatient, primary care), costs, mortality and diagnoses were included. Data from the Swedish Prescribed Drug register were included from July 1, 2005 until December 31, 2007. Diffi cult-totreat NeP was defi ned as patients with a NeP diagnosis in 2006, who had had 2 prescriptions of at least three pain medications during one year from the index diagnosis date. The patients should also have had two or more prescriptions of pregabalin preceded by at least a six months pregabalin naïve period. RESULTS: A total of 462 diffi cult-to-treat NeP patients met the above criteria and were included in the analyses. There was a statistically signifi cant reduction in NeP related costs (visits registered with a NeP diagnosis) after initiation of pregabalin (p = 0.0042 Mann-Whitney). The mean per patient NeP related costs were SEK17,684 (c1,845) 6 months before and SEK10,642 (c1,110) 6 months after pregabalin initiation. The mean non-NeP related costs before treatment (SEK46,095; c4,809) did not differ signifi cantly from the non-NeP costs after treatment (SEK 51, 632; c5, 387) , p = 0.8016. The number of NeP-related in-patient visits, primary care visits and the number of days in hospital decreased signifi cantly (p = 0.0475, p = 0.0129, p = 0.0179, respectively) after treatment with pregabalin. CONCLUSIONS: Initiation of pregabalin signifi cantly reduced the NeP related health care costs in the 6-month period following initiation. Of note was the non signifi cant difference in non-NeP related costs, probably refl ecting the on-going costs associated with management of the patients' concurrent conditions, eg, diabetes.
PSY14 REAL-WORLD USE OF DULOXETINE FOR CHRONIC LOW BACK PAIN: TREATMENT PATTERN AND COSTS
Ivanova JI 1 , Birnbaum HG 2 , Kantor E 2 , Schiller M 2 , Swindle R 3 1 Analysis Group, Inc., New York, NY, USA; 2 Analysis Group, Inc., Boston, MA, USA; 3 Eli Lilly & Company, Indianapolis, IN, USA OBJECTIVES: Examine the real-world role of duloxetine versus other treatment for chronic low back pain (CLBP). METHODS: Study sample was selected from a U.S. privately-insured claims database (2004) (2005) (2006) (2007) (2008) . Selection criteria: ages 18-64 years, had a low back pain (LBP) diagnosis (per HEDIS specifi cations) with a subsequent CLBP-qualifying diagnosis recorded 90 days or more after the initial LBP diagnosis. Duloxetine-treated patients had ≥1 duloxetine prescription within 6 months after CLBP diagnosis, no prior duloxetine claim, and continuous eligibility ≥12 months before fi rst LBP diagnosis and ≥6 months after index duloxetine prescription (study period). 553 duloxetine-treated patients were matched to a total of 553 control patients who initiated another non-surgical LBP treatment based on propensity score and time from fi rst LBP diagnosis to treatment initiation. a subset (n = 103 each) of matched employees was also analyzed. McNemar tests were used to compare LBP treatment rates. Bias-corrected bootstrapping was used to compare direct (medical and drug) costs from third-party payer perspective and employee indirect (workloss) costs. RESULTS: During the 6-month study period, matched duloxetine-treated patients had signifi cantly lower rates of other pharmacological therapy than controls (e.g., 56.2% vs. 64.9% narcotic opioids, p = 0.002; 34.9% vs. 49.5% NSAIDs; P < 0.001) and non-invasive therapy (28.8% vs. 38.5% chiropractic therapy; 25.5% vs. 35.4% physical therapy; 17.5% vs. 28.4% exercise therapy; all P < 0.001). Duloxetine-treated patients versus controls had numerically lower back surgery rates (2.2% vs. 3.8%, p = 0.117) and similar direct costs ($7658 vs. $7439, p = 0.812). Among CLBP employees, duloxetine-treated employees versus controls had lower rates of other non-surgical therapy, numerically lower back surgery rates (0% vs. 3.9%, p = 0.125), lower total direct and indirect costs ($5227 vs. $7229, p = 0.042), and numerically lower indirect costs ($1806 vs. $2664, p = 0.053). CONCLUSIONS: Duloxetine treatment in CLBP patients/employees versus other non-surgical treatment was associated with reduced rates of non-surgical therapies and numerically lower surgery rates without increased costs.
PSY15 CONSTIPATION RELATED TO OPIOID THERAPY: A COST-OF-ILLNESS AND PREVALENCE DATABASE STUDY IN THE BRAZILIAN PRIVATE SETTING
Takemoto ML 1 , Fernandes RA 1 , Passos RB 1 , Colombini-Netto M 2 , Bertola-Neto A 2 , Almeida GR 3 , Monteiro R 3 1 ANOVA-Knowledge Translation, Rio de Janeiro, RJ, Brazil; 2 Axismed Gestão Preventiva da Saúde, São Paulo, SP, Brazil; 3 Pfi zer, São Paulo, SP, Brazil OBJECTIVES: To estimate the prevalence of constipation concomitant to opioid treatment and related resource utilization and costs from the private payer perspective. METHODS: Patients on opioid therapy were identifi ed from a longitudinal insurance claims database consisting in 1,057,033 individuals for a period of 35 months. An algorithm was used to identify patients on opioid therapy with coincident constipation-related claims according to ICD-10 codes, targeted procedures and opioid use criteria. Resource utilization and costs were determined for these individuals and compared with patients on opioid therapy without constipation, without opioid therapy with constipation and without both conditions. Results were compared using ANOVA with a signifi cance level of 0.05 and are presented per individual per month. RESULTS: A total of 23,313 patients were classifi ed as opioid treated patients (2.21% of total population) and 6,678 had events related to constipation (29.03% of the opioid population). Compared with opioid treated patients without constipation, incremental mean total costs per month per patients with the condition were 261.18 BRL (P < 0.001). The average cost per month for opioid-related constipation patients was 787.84 BRL, signifi cantly higher than patients on opioid therapy without constipation (526.66 BRL), with no opioid therapy but constipated (284.47 BRL) and without both (90.17 BRL) (P < 0.001 for all comparisons). Patients with claims related to both conditions had signifi cantly more days in hospital per month (0.25 vs. 0.497, P < 0.001), outpatient offi ce visits (1.04 vs. 1.59, P < 0.001), outpatient procedures (4.69 vs. 14.05, P < 0.001) and tests and therapies (31.95 vs. 36.66, P < 0.001) than did patients without opioid-related constipation claims. CONCLUSIONS: The economic burden of patients with constipation events coincident with opioid treatment is signifi cantly higher when compared to all other groups. Constipated patients without opioid therapy had also higher costs than those free of both conditions. These results indicate that reducing opioid-induced constipation has potential cost savings for the health care system.
